NCT06503146 - 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection | Biotech Hunter

Enrollment

320

Participants

Timeline

Start Date

September 9, 2025

Primary Completion Date

June 1, 2028

Study Completion Date

June 1, 2030

Conditions

SarcomaSmall Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC)MesotheliomaPheochromocytoma/Paraganglioma (PPGL)Pancreatic Ductal AdenocarcinomaOvarian CancerHepatocellular CarcinomaGastric CancerCholangiocarcinomaBladder Cancer

Interventions

DRUG

[18F]FAPI-74

Participants will receive a single intravenous (IV) dose of \[18F\]FAPI-74 prior to PET/CT imaging.

DRUG

[18F]FDG

18F-FDG PET/CT or PET/MRI imaging will be done per standard of care.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH